Genetics Pharma Companies RNA Vaccine 
pharmaphorum
JANUARY 10, 2022
The arrival of COVID-19 brought precious few positives, but one that emerged for the pharmaceutical industry was the emergence and validation of mRNA vaccine technology to prevent disease. Pfizer already has a head start on competitors in the field, having achieved the first US FDA approval for an mRNA vaccine, alongside BioNTech.
XTalks
DECEMBER 22, 2021
The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The power of its real-world application was demonstrated by the resounding success of the mRNA COVID-19 vaccines. RNA in the Making.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 13, 2023
These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. vaccine, mRNA-1273.815.
pharmaphorum
JANUARY 6, 2021
Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. — Tinglong Dai (@TinglongDai) January 5, 2021.
pharmaphorum
DECEMBER 21, 2020
Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. Just who are these companies and who is behind them, asks Richard Staines. A year ago, the names Moderna and BioNTech were known mainly to those who followed biotech and pharma dealings.
pharmaphorum
AUGUST 23, 2022
With COVID-19 vaccines and therapeutics developed in rapid time, Ben Hargreaves investigates why this has not been the case with the creation of a treatment for Long COVID. Once the scale of the threat was understood, the pharmaceutical industry reacted with a rapidity and agility that allowed vaccines to be developed at a record rate.
Drug Discovery World
NOVEMBER 15, 2022
If a pharmaceutical company is racing to identify a new vaccine, for instance, then waiting for three weeks to receive DNA sequences each time can slow down the development process compared to competitors who might have faster timelines.” . The longer the DNA gets, the longer it will take for labs to receive it,” notes Dr Daniels. “If
Expert insights. Personalized for you.
99 
Let's personalize your content